- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02334449
First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers (LML134)
A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability and Pharmacokinetics of LML134 in Healthy Volunteers
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, 14050
- Novartis Investigative Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Healthy male and female subjects age 18 to 55 years of age included, and in good health as determined by medical history, physical examination, vital signs, electrocardiogram, and laboratory tests.
- Written informed consent must be obtained before any assessment is performed.
- Able to communicate well with the Investigator, to understand and comply with the requirements of the study.
Exclusion Criteria:
- History or presence of epilepsy or of seizures or convulsions of any kind.
- Any clinically relevant abnormalities identified in the resting EEG during screening, or pre-ictal signs or other clinically relevant abnormalities in the hyperventilation or intermittent photic stimulation EEG during screening.
- History of head trauma leading to clinically significant symptoms in the past two years.
- Applies only to subjects enrolled in Part 2 MAD. Score "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self-Injurious Behavior" (item also included in the Suicidal Behavior section), if this behavior occurred in the past 2 years.
- Significant illness including any clinically significant infectious disease which has not resolved within two (2) weeks prior to initial dosing.
- History or presence of significant hematological abnormalities or immunodeficiency or any condition that might compromise the immune system (infection, vaccination), of any etiology as indicated by clinically significantly abnormal values of any of the following hematologic parameters: thrombocyte, RBC count, total WBC count and differentials presented as % of total white blood cell count and as absolute concentrations.
- History or presence of any thyroid disease as indicated by any clinically relevant abnormality on thyroid stimulating hormone test (TSH).
- History or presence of any chronic eye disease other than refractive error, strabismic amblyopia, or anisometropic amblyopia.
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Single dose study part
there will be 8 cohorts of healthy volunteers dosed with single doses of LML134 (8 planned dose levels) or with placebo and 2 potential additional cohorts (also dosed with single dose of LML134 or placebo)
|
LML134 will be administered first as single doses and then as multiple doses
All study cohorts (except food effect cohort) are placebo controlled
|
Experimental: Multiple dose study part
there will be 3 cohorts of healthy volunteers dosed with multiple doses of LML134 (3 planned dose levels) or placebo and one potential additional cohort (also dosed with multiple doses of LML134 or placebo)
|
LML134 will be administered first as single doses and then as multiple doses
All study cohorts (except food effect cohort) are placebo controlled
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Avaliações de eventos adversos após administração de dose ascendente única e múltipla no início do estudo e repetidamente até a conclusão do estudo
Prazo: Começando cerca de 24 horas antes da administração e continuando até cerca de 7-14 dias após a última dose
|
Este resultado de segurança combina a medida do número de indivíduos que sofreram eventos adversos (EAs), a natureza e a gravidade desses AEs e sua relação com os tratamentos do estudo.
|
Começando cerca de 24 horas antes da administração e continuando até cerca de 7-14 dias após a última dose
|
Cardiovascular safety assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion
Prazo: Starting about 24 hours before dosing and continued until about 7-14 days after last dose
|
This safety outcome combines the measure of a set of cardiovascular safety parameters extracted from ECGs, 25 hours-Holter ECGs and from vital signs assessments
|
Starting about 24 hours before dosing and continued until about 7-14 days after last dose
|
Central nervous system safety assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion
Prazo: Starting about 24 hours before dosing and continued until about 7-14 days after last dose
|
This safety outcome combines the measure of a set of central nervous system safety parameters extracted from EEGs and neurological examinations
|
Starting about 24 hours before dosing and continued until about 7-14 days after last dose
|
Ocular safety assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion
Prazo: Starting about 24 hours before dosing and continued until about 7-14 days after last dose
|
This safety outcome combined the measure of a set of ocular parameters including best corrected visual acuity and other parameters assessed by the mean of slit lamp biomicroscopy and dilated ophthalmoscopy examinations and by optical coherence tomography and electroretinography
|
Starting about 24 hours before dosing and continued until about 7-14 days after last dose
|
General safety assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion
Prazo: Starting about 24 hours before dosing and continued until about 7-14 days after last dose
|
This general safety outcome combines the measure of blood laboratory parameters and the outcome of physical examinations
|
Starting about 24 hours before dosing and continued until about 7-14 days after last dose
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Pharmacokinetics (PK) of LML134: time to reach the maximum concentration after a single drug administration (Tmax) in Part 1 and in Part 3
Prazo: Starting 1hour prior to dosing on Day 1 and until 72 hours after dosing (Day 4)
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 2: 24h and 36h post dose, on Day 3: 48h and 60h post dose and on Day 4: 72h post dose. This outcome measure shows the mean of all subject values resulting from each time point specified above, in Parts 1 and 3. In Part 3, the outcome measure is done once without food intake and once after the intake of a high fat breakfast (in 2 different periods). Both outcomes (with and without breakfast intake) will be compared to assess the effect of a high fast breakfast on LML134 Tmax |
Starting 1hour prior to dosing on Day 1 and until 72 hours after dosing (Day 4)
|
PK of LML134: Observed maximum serum concentration following single drug administration (Cmax) in Part 1 and Part 3
Prazo: Starting 1hour prior to dosing on Day 1 and until 72 hours after dosing (Day 4)
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 2: 24h and 36h post dose, on Day 3: 48h and 60h post dose and on Day 4: 72h post dose. This outcome measure shows the mean of all subject values resulting from each time point specified above, in Parts 1 and 3. In Part 3, the outcome measure is done once without food intake and once after the intake of a high fat breakfast (in 2 different periods). Both outcomes (with and without breakfast intake) will be compared to assess the effect of a high fast breakfast on LML134 Cmax. |
Starting 1hour prior to dosing on Day 1 and until 72 hours after dosing (Day 4)
|
PK of LML134: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) in Part 1 and Part 3
Prazo: Starting 1hour prior to dosing on Day 1 and until 72 hours after dosing (Day 4)
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 2: 24h and 36h post dose, on Day 3: 48h and 60h post dose and on Day 4: 72h post dose.
This outcome measure shows the mean of all subject values resulting from each time point specified above, in Parts 1 and 3.
In Part 3, the outcome measure is done once without food intake and once after the intake of a high fat breakfast (in 2 different periods).
Both outcomes (with and without breakfast intake) will be compared to assess the effect of a high fast breakfast on LML134 AUClast.
|
Starting 1hour prior to dosing on Day 1 and until 72 hours after dosing (Day 4)
|
PK of LML134: time to reach the maximum concentration after the first drug administration (Tmax) in Part 2
Prazo: Starting 1hour prior the first dose administration (Day 1) until 24hr after the first dose administration on Day 2
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose and on Day 2: 24h post dose.
This outcome measure shows the mean of all subject values resulting from each time point specified above.
|
Starting 1hour prior the first dose administration (Day 1) until 24hr after the first dose administration on Day 2
|
PK of LML134: time to reach the maximum concentration after the last drug administration (Tmax) in Part 2
Prazo: Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 2: 24h post dose, on Day 3: 1hr prior the second dose administration, on Days 4, 5, 6, 8, 10, 12, 13, 14: 1hr prior dosing, on Day 15 (last time the drug is administered): 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 16: 24h post dose and Day 17: 48h post dose.
This outcome measure shows the mean of all subject values resulting from each time point specified above.
|
Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
PK of LML134: Observed maximum serum concentration following the first drug administration (Cmax) in Part 2
Prazo: Starting 1hour prior the first dose administration (Day 1) until 24hr after the first dose administration on Day 2
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose and on Day 2: 24h post dose.
This outcome measure shows the mean of all subject values resulting from each time point specified above.
|
Starting 1hour prior the first dose administration (Day 1) until 24hr after the first dose administration on Day 2
|
PK of LML134: Observed maximum serum concentration following drug administration at steady state (Cmax,ss) in Part 2
Prazo: Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 2: 24h post dose, on Day 3: 1hr prior the second dose administration, on Days 4, 5, 6, 8, 10, 12, 13, 14: 1hr prior dosing, on Day 15 (last time the drug is administered): 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 16: 24h post dose and Day 17: 48h post dose.
This outcome measure shows the mean of all subject values resulting from each time point specified above.
|
Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
PK of LML134: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) after the first dose administration in Part 2
Prazo: Starting 1hour prior the first dose administration (Day 1) until 24hr after the first dose administration on Day 2
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose and on Day 2: 24h post dose.
This outcome measure shows the mean of all subject values resulting from each time point specified above.
|
Starting 1hour prior the first dose administration (Day 1) until 24hr after the first dose administration on Day 2
|
PK of LML134: The area under the serum concentration-time curve from time zero to the end of the dosing interval tau at steady state (AUCtau,ss) in Part 2
Prazo: Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 2: 24h post dose, on Day 3: 1hr prior the second dose administration, on Days 4, 5, 6, 8, 10, 12, 13, 14: 1hr prior dosing, on Day 15 (last time the drug is administered): 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 16: 24h post dose and Day 17: 48h post dose.
This outcome measure shows the mean of all subject values resulting from each time point specified above.
|
Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
PK of LML134: The average steady state serum concentration during multiple dosing (Cav,ss) in Part 2
Prazo: Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 2: 24h post dose, on Day 3: 1hr prior the second dose administration, on Days 4, 5, 6, 8, 10, 12, 13, 14: 1hr prior dosing, on Day 15 (last time the drug is administered): 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 16: 24h post dose and Day 17: 48h post dose.
This outcome measure shows the mean of all subject values resulting from each time point specified above.
|
Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
PK of LML134: The effective half-life based on drug accumulation at steady state (T1/2,acc) in Part 2
Prazo: Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 2: 24h post dose, on Day 3: 1hr prior the second dose administration, on Days 4, 5, 6, 8, 10, 12, 13, 14: 1hr prior dosing, on Day 15 (last time the drug is administered): 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 16: 24h post dose and Day 17: 48h post dose.
This outcome measure shows the mean of all subject values resulting from each time point specified above.
|
Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
PK of LML134: The accumulation ratio (Racc) in Part 2
Prazo: Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
Serum samples will be collected on Day 1: 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 2: 24h post dose, on Day 3: 1hr prior the second dose administration, on Days 4, 5, 6, 8, 10, 12, 13, 14: 1hr prior dosing, on Day 15 (last time the drug is administered): 1hr predose; 0,25h; 0,5h; 1h; 1,5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h post dose, on Day 16: 24h post dose and Day 17: 48h post dose.
This outcome measure shows the mean of all subject values resulting from each time point specified above.
|
Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Study Director, Novartis Pharmceuticals
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- CLML134X2101
- 2014-000937-22 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .